Zemplar

Paricalcitol is a vitamin D analog used to manage secondary hyperparathyroidism in chronic kidney disease. This intravenous form helps regulate calcium and phosphorus levels. Commonly prescribed for dialysis patients, it supports bone health. Short-term use under medical supervision is typical.

Paricalcitol is primarily used to treat secondary hyperparathyroidism in patients with chronic kidney disease, particularly those on dialysis. It works by reducing elevated parathyroid hormone levels, which can otherwise weaken bones over time. The medication is often prescribed when dietary adjustments and phosphate binders alone are insufficient. It may also be considered for patients not yet on dialysis but with significant parathyroid hormone elevation.

Paricalcitol helps balance calcium and phosphorus levels in the blood, which supports overall bone health. Patients may experience improved energy levels and reduced symptoms related to high parathyroid hormone, such as bone pain or muscle weakness. Some individuals notice gradual normalization of lab values over time with consistent use.

Store paricalcitol in a cool, dry place away from direct light. Keep out of reach of children and pets. If the solution appears discolored or contains particles, do not use it. Always check the expiration date before administration. Discard any unused medication as directed by a healthcare provider.

Paricalcitol may interact with other medications that affect calcium or vitamin D levels, such as thiazide diuretics or calcium supplements. High doses of calcium or phosphate binders can increase the risk of hypercalcemia. Inform your healthcare provider about all medications, including over-the-counter products and supplements, before starting paricalcitol.